secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2022-12-21T23:59:59+00:00
Accession:  0001104659-22-128864
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax issues $150M 5% convertible notes due 2027; net proceeds $142.2M
------------------------------------------------------------------------

- $150M principal, 5.00% semiannual interest, matures Dec 15, 2027; net proceeds ~$142.2M after discounts.
- Proceeds: global launch of Nuvaxovid, repay/repurchase part of $325M 3.75% notes due Feb 2023, working capital, R&D.
- Initial conversion price $12.50/share (80 shares per $1,000); 25% premium over concurrent common stock offering.
- Maximum shares issuable upon conversion: 15M shares based on initial max conversion rate of 100 shares per $1,000.
- Initial purchasers have 30-day option to buy additional $25.25M principal amount of notes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465922128864/0001104659-22-128864-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465922128864/tm2232888d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-128864

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer